Efficacy and Safety of Carfilzomib, Dexamethasone, Daratumumab (KdD) Twice-Weekly at 56 mg/m(2) and Once-Weekly at 70 mg/m(2) in Relapsed or Refractory Multiple Myeloma (RRMM): Cross-Study Comparison of the CANDOR and EQUULEUS studies
Por:
Leleu, X, Beksac, M, Chou, T, Dimopoulos, M, Yoon, SS, Prince, HM, Pour, L, Shelekhova, T, Chari, A, Khurana, M, Obreja, M, Qi, M, Oriol, A and Siegel, D
Publicada:
1 sep 2020
Resumen:
Filiaciones:
Leleu, X:
Chu, Poitiers, France
Inserm 1402CIC, Poitiers, France
Beksac, M:
Ankara Univ, Ankara, Turkey
Chou, T:
Niigata Canc Ctr Hpt, Niigata, Japan
Dimopoulos, M:
Natl & Kapodistrian Univ Athens, Sch Med, Hematol & Med Oncol, Dept Clin Therapeut,Sch Med, Athens, Greece
Yoon, SS:
Seoul Natl Univ, Seoul, South Korea
Prince, HM:
Peter MacCallum Canc Inst, East Melbourne, Australia
Pour, L:
Univ Hosp Brno, Brno, Czech Republic
Shelekhova, T:
Clin Profess Pathol, Saratov, Russia
Chari, A:
Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA
Khurana, M:
Amgen Inc, Thousand Oaks, CA USA
Obreja, M:
Amgen Inc, Thousand Oaks, CA USA
Qi, M:
Janssen Res & Dev LLC, Spring House, PA USA
:
Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Barcelona, Spain
Siegel, D:
Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
|